OR WAIT null SECS
The latest people news happenings over the past month
Piramal Pharma Ltd (PPL), a company that offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities, announced the addition of three members to its board of directors: Peter Stevenson, Sridhar Gorthi, and Nathalie Leitch. Stevenson brings in-depth knowledge in contract manufacturing, business operations, supply chain management, and operating in complex regulatory environment, while Gorthi is an authority in corporate law, M&A, and private equity. His experience spans across manufacturing, pharmaceuticals, insurance, banking and financial services, technology, telecom and media. Leitch is a subject matter expert in pharma and the US generics industry, with experience in creative product strategies and formulations.
Inspira Health, a charitable nonprofit health care organization, has appointed Tony S. Reed, MD, to senior vice president, chief quality, and safety officer, effective Aug. 1. In this role, Dr. Reed will focus on executing and expanding Inspira’s role through patient safety, quality, and excellence.
The board of directors has appointed Thomas Schinecker, PhD, currently CEO of the diagnostics division, to CEO of Roche succeeding Severin Schwan. The move is effective March 15, 2023. Schinecker holds a PhD in molecular biology and has been working for Roche in different leadership positions since 2003.
Fortress Biotech, Inc., a biopharma company, has appointed David Jin as chief financial officer, effective Aug. 16. He will also continue to serve as head of corporate development. Jin has been a member of the Fortress team since 2020 and also serves as interim CEO and chief financial officer of Avenue Therapeutics, a Fortress partner company. The appointment follows notice from Chief Financial Officer Robyn Hunter that, also effective the same day, she will step down from Fortress after 11 years with the company to pursue external opportunities.
CoreRx, Inc., a contract development and manufacturing organization (CDMO), has brought on Dan Dobry as its chief strategy officer and a member of CoreRx’s executive leadership team. He will be reporting to CoreRx’s CEO, Ajay Damani. In his role, Dobry will oversee CoreRx’s strategy and corporate development functions.
Avantor, Inc., a provider of products and services to customers in the life sciences industry, has appointed veteran strategy and M&A executive, Kitty Sahin, to the newly created role of executive vice president, strategy and corporate development, effective immediately. In this role, she will report to president and CEO Michael Stubblefield. Sahin will be responsible for leading the company's strategy and corporate development team to shape, and executing the enterprise growth strategy through organic and inorganic initiatives.
The Center for Breakthrough Medicines (CBM), a CDMO for the cell and gene therapy sector, has appointed Mandy Conver as SVP of business development for testing & analytics, and Jennifer Manning as SVP of global strategic partnerships. Conver will be responsible for leading and directing a team toward repeated success, while driving revenue growth via organic and new business opportunities. As for Manning, with more than 25 years of bioprocessing and cell and gene therapy experience, she will negotiate, develop, and lead strategic partnerships with academic institutions, private equity and venture capital firms, and large pharma at CBM.
ParcelShield Holdings, LLC, a provider of technology-enabled predictive parcel tracking and patient engagement solutions for the healthcare industry, announced that its board of directors has appointed Kirk Nilson as its new CEO, effective Aug. 8. He will succeed Guillermo Sollberger, who will continue to support the ParcelShield board in an advisory role.
TrialCard Incorporated, a full-service life sciences commercialization partner, has promoted Scott Dulitz to CEO. Dulitz, a pharma services industry veteran of 20 years, joined the company in 2015, and most recently served as president and chief strategy officer.